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ABSTRACT 
Aim of the study: The present study is undertaken to evaluate the effect of Euphorbia neriifolia 
stem bark on blood glucose and lipid levels in experimental diabetic rats. 
Methodology: Methanolic extract of Euphorbia neriifolia stem bark (MEEN) was administered 
at different doses and  its  effect on blood glucose, haemoglobin , serum and tissue lipids, 
hexokinase and glucose-6-phosphatase in streptozotocin-induced diabetic rats were studied. 
Glibenclamide was used as standard reference drug. 
Results: Euphorbia neriifolia Methanolic extract (MEEN), at doses of 100,200 and 400mg/kg 
body weight for 30 days, suppressed the elevated blood glucose and lipid levels in diabetic rats. 
Euphorbia neriifolia at 400mg/kg was found to be comparable to glibenclamide. 
Conclusion: The study indicates that the Euphorbia neriifolia possess antihyperlipidaemic effect 
as well as antidiabetic activity. 
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INTRODUCTION 
Diabetes mellitus and blood glucose homeostasis 
Diabetes mellitus is a principal cause of morbidity and mortality in human populations [1]. It is a 
syndrome characterized by hyperglycemia, polydipsia and polyuria and causes complications to 
the eyes, kidneys, and nerves. It is also associated with an increased incidence of cardiovascular 
disease [2]. The clinical manifestations and development of diabetes often differ significantly 
between countries and also between racial groups within a country. For example, diabetes 
currently affects an estimated 15.1 million people in North America, 18.5 million in Europe, 51.4 
million in Asia, and just under 1 million in Oceania [3]. It is estimated that globally, the number 
of people will rise from 151 million in the year 2000[4], to 221 million by the year 2010, and to 
300 million by 2025[5]. 
The International Diabetes Federation (IDF) estimates the total number of diabetic subjects to be 
around 40.9 million in India and this is further set to rise to 69.9 million by the year 2025[6,7] . 
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The clinical diagnosis of diabetes is often suggested by the presence of hyperglycemic symptoms 
and glycosuria, sometimes with drowsiness or coma. The World Health Organization (WHO) 
 criteria define diabetes by fasting plasma glucose (FPG) level of 140mg/dL (7 mmol/L) or 
greater, or post-prandial 2-h plasma glucose (PG) level of 200mg/dL (11.1 mmol/L) or greater 
during an oral glucose tolerance test [8]. The National Diabetes Data Group of the National 
Institutes of Health recommends the following criteria for diagnosing diabetes:  
 Fasting (overnight) venous plasma glucose concentration greater than or equal to 140 
mg/dL on at least two separate occasions.  
 Venous plasma glucose concentration greater than or equal to 200 mg/dL at 2-h post-
ingestion of 75 g of glucose and at least one other sample during the 2-h test. 
Euphorbia neriifolia L. (Euphorbiaceae, common name: Indian Spurge Tree) a common plant in 
India, has been widely used in traditional medicine as a cure for  aphrodisiac, diuretic, cough and 
cold,   and   also   used   in   the   treatment of   bronchitis, bleeding piles, ano-rectal fistula
 
. In 
addition, roots as antispasmodic, the root mixed with black pepper is applied to cure snake bites. 
Papiya Bigoniya et al [9] evaluated the hepatoprotective activity of saponin fraction isolated 
from leaf of E. neriifolia on CCl4 induced heaptotoxicity. CCl4 (5mg/kg; ip) induces peroxidative 
degeneration of membrane lipids causing hypo perfusion of membrane. Kalpesh Gaur et al [10] 
determined the immunomodulatory activity of 70% v/v hydro-alcoholic extract of dried leaves of 
E.neriifolia by oral administration at dose of 400mg/kg/day of body weight to healthy albino 
rats. This study was thus initiated with the aim of evaluating the effects of Methanolic extract of 
Euphorbia neriifolia stem bark (MEEN) on the blood glucose level, serum and tissue lipids in 
streptozotocin diabetic rats. 
MATERIALS AND METHODS 
Animals 
All the experiments were carried out with male Wistar rats aged seven to eight weeks (180-200 
g), obtained from the Central Animal House, Y.B.Chavan College of Pharmacy, 
B.A.M.University, Aurangabad India. The animals were housed in polypropylene cages and 
provided with water and standard pellet diet ad libitum. The animals used in the present study 
were approved by the institutional Animal Ethics Committee 
Chemicals 
Streptozotocin was obtained from Himedia Laboratory Limited, Mumbai, India. All other 
reagents used were of analytical grade. 
Plant Material 
Euphorbia neriifolia stem bark collected freshly from Dhule and Nandurbar District, 
Maharashtra, India. The plant was identified and authenticated at the Herbarium of Botany 
Department of the University.  
Preparation of plant extract 
Five hundred g of Euphorbia neriifolia stem bark extracted with 1,500 ml of methanol by the 
method of continuous hot extraction at 60ºC for six hours and evaporated. The residual extract 
was used in the study
 
[11]. 
Induction of experimental diabetes 
A freshly prepared solution of streptozotocin (45 mg/kg i.p) in 0.1 M citrate buffer, pH 4.5 was 
injected intraperitoneally in a volume of 1 ml/kg. After 48 hours of streptozotocin 
administration, rats with moderate diabetes having glycosuria and hyperglycaemia (i.e. with a 
blood glucose of 200-300 mg/dl) were taken for the experiment
 
[12]. 
 
Experimental procedure 
In this study, a total of 36 rats (30 diabetic surviving rats, six normal rats) were used. The rats 
were divided into six groups of six rats each. 
 Group 1:  Normal untreated rats. 
Group 2: Diabetic control rats given 1 ml of aqueous solution daily using an intragastric tube for 
30 days. 
Group 3: Diabetic rats given MEEN (100mg/kg body weight) suspended in 0.5% CMC daily 
using an intragastric tube for 30 days. 
Group 4: Diabetic rats given MEEN (200mg/kg body weight) suspended in 0.5% CMC daily 
using an intragastric tube for 30 days. 
Group 5: Diabetic rats given MEEN (400mg/kg body weight) suspended in 0.5% CMC daily 
using an intragastric tube for 30 days. 
Group 6: Diabetic rats given glibenclamide (600 µ g/ kg body weight)
 
[13] suspended in 0.5% 
CMC daily using an intragastric tube for 30 days. 
At the end of 30 days, the animals were deprived of food overnight and sacrificed by 
decapitation. Blood was collected in two different tubes (i.e.,) one with anticoagulant- potassium 
oxalate and sodium fluoride for plasma and another without anticoagulant for serum separation. 
Plasma and serum were separated by centrifugation.  Liver was immediately dissected out, 
washed in ice cold saline, patted dry and weighed. 
Analytical Procedure 
Fasting blood glucose was estimated by O-toluidine method [14]. Plasma insulin level was 
assayed by Enzyme Linked Immunosorbent Assay (ELISA) kit, using human insulin as standard. 
Haemoglobin was estimated by the method of Drabkin and Austin
 
[15] .Lipids was extracted 
from serum and tissues by the method of Folch et al [16]. Total cholesterol and triglycerides 
were estimated by the method of Zlatkis et al [17] and Foster and Dunn [18] respectively. Free 
fatty acids and phospholipids were analysed by the method of Falholt et al [19] and Zilversmit et 
al [20]. 
Hexokinase and glucose-6-phosphatase were assayed by the method of Brandstrup et al [21]
  
 
and Koida and Oda[22]. 
Statistical analysis 
All values were expressed as the mean obtained from a number of experiments (n). Data from all 
the tables of normal animals, diabetic control animals, reference drug treated and MEEN treated 
animals were compared by ANOVA followed by Duncan’s Multiple Range Test (DMRT) [23]. 
RESULTS 
Blood glucose and Plasma insulin 
Table I shows the levels of blood glucose, plasma insulin, total haemoglobin, , changes in body 
weight and urine sugar of normal and experimental rats. There was a significant elevation in 
blood glucose, while the plasma insulin and total haemoglobin levels decreased significantly in 
streptozotocin diabetic rats when compared with normal rats. Administration of MEEN and 
glibenclamide tends to bring the parameters significantly towards the normal. The effect of 
MEEN at a dose of 400mg/kg body weight was more highly significant than 100 and 200mg/kg 
body weight and therefore the dose was used for further biochemical studies. 
In diabetic rats, the urine sugar was (+++) but in the case of MEEN treated rats at a dose of 
100 and 200mg/kg body weight showed decreased urine sugar (++) and (+) respectively. MEEN 
at a dose 400mg/kg of body weight, showed urine sugar as seen in normal rats. These effects 
were compared with glibenclamide. 
 
 
 
 
 
 Table I. Blood glucose, plasma insulin, total haemoglobin, glycosylated haemoglobin, changes in 
body weight and urine sugar of normal and experimental animals. 
 
 
 
FBG-Fasting Blood Glucose  
Values are given as mean    S.D. for six rats in each group. 
 
Values not sharing a common superscript letter differ significantly at p < 0.05(DMRT). 
 
 
Diabetic control was compared with normal, 
•••
 p<0.001. 
Experimental groups were compared with diabetic control, 
***
 p<0.001. 
A - Indicates 0.25% sugar and (+ + +) indicates more than 1% sugar. 
Serum and tissue lipids 
The effect of   MEEN on serum and tissue lipids of normal and experimental rats is summarized 
in Table II and III respectively. A marked increase in the frequency of cholesterol, free fatty 
acids, triglycerides and phospholipids were observed in diabetic control rats. Treatment with 
MEEN significantly reduced the lipid levels. 
 
Table II. Changes in levels of cholesterol, free fatty acids, triglycerides and phospholipids in 
serum of normal and experimental animals. 
Groups Cholesterol 
mg/100ml 
Free Fatty Acids 
mg/100ml 
Triglycerides 
mg/100ml 
Phospholipids 
mg/100ml 
Normal 78.25 4.56
a 
67.43  a
 
43.96 ±  3.27
a a
 
Diabetic Control 97.66 b
 
81.86 b
 
61.83 ± 1.50
b b 
Diabetic+MEEN(400mg/kg) 85.34 ±5.43
c 
73.05  c
 
52.87 ± 2.70
c c
 
Diabetic+Glibenclamide(600µg/kg) 91.00d
 
76.51  d
 
57.46  ± 1.70
d d 
Values are given as mean  S.D for six rats in each group. 
Values not sharing a common superscript letter differ significantly at p<0.05 (DMRT). 
Table III. Changes in levels of cholesterol, free fatty acids, triglycerides and phospholipids in 
liver of normal and experimental animals. 
Groups Cholesterol 
mg/100gm wet 
tissue 
Free Fatty Acids 
mg/100gm wet tissue 
Triglycerides 
mg/100gm wet tissue 
Phospholipids 
g/100gm wet tissue 
Normal 345.04 2.55 646.50  30.66 358.79  11.90 1.05  
Diabetic Control 522.70 5.88 895.34  50.49 615.87  7.86 2.34  
Diabetic+MEEN(400mg/kg) 418.544.30 792.09  47.35 440.76  12.57 2.00  
Diabetic+Glibenclamide(600µg/kg) 457.895.36 801.56  24.30 534.81  11.43 2.30  
Values are given as mean ± S.D for six rats in each group. 
Values not sharing a common superscript letter differ significantly at p<0.05 (DMRT). 
Groups Body Weight(g) 
Initial            Final        
FBG 
(mg/dl) 
Plasma 
Insulin (IU/ml) 
Hgb(g/dl) Urine 
Sugar 
Normal 201  213± 8.90 87.12±1.24
a 
7.74 ± 0.41
a 
13.01 0.71a Nil 
Diabetic Control  155±11.54
***
 296.56±4.87
b 
3.50 ± 0.73
b 
5.96 0.56b +++ 
Diabetic+MEEN(100mg/kg)  
***
 150.65±3.72
b 
 6.84 0.66
c 
++ 
Diabetic+MEEN(200mg/kg)  214
***
 135.82±2.12
c 
3.01± 0.36
c 
9.55 0.93d + 
Diabetic+MEEN(400mg/kg)  
***
 115.32±1.76
ad 
5.476± 0.30
d 
11.780.89e Nil 
Diabetic+Glibenclamide 
(600µg/kg) 
 
***
 89.21±0.87
d 
7.58 ± 0.72
e 
10.24 1..01d Trace 
 Duncan procedure, Range for the level 2.95, 3.09, 3.20. 
Hepatic hexokinase and glucose-6-phosphatase 
The activities of carbohydrate enzymes are represented in Table IV. Activity of hexokinase in 
liver decreased markedly while the glucose-6-phosphatase activity increased significantly in 
diabetic control rats. Treatment with MEEN in diabetic rats increased the hexokinase activity and 
decreased the glucose-6-phosphatase activity. 
Table IV. Changes in activities of hexokinase and glucose-6-phosphatase in liver of normal and 
experimental animals. 
Groups Hexokinase 
(units
A
/g protein) 
Glucose- 6-phosphatase 
(units
B
/mg protein) 
Normal 139.31  0.159  0.014 
Diabetic Control 101.48 4.85 0.257   0.025  
Diabetic+MEEN(400mg/kg) 130.01  7.69 0.189  0.011 
Diabetic+Glibenclamide(600µg/kg) 126.56 4.94 0.204  
 
Values are given as mean ± S.D for six rats in each group. 
Values not sharing a common superscript letter differ significantly at p<0.05 (DMRT). 
Duncan procedure range for the level 
DISCUSSION 
Streptozotocin is well known for its selective pancreatic islet β -cell cytotoxicity and has been 
extensively used to induce diabetes mellitus in animals. It interferes with cellular metabolic 
oxidative mechanisms [24]. Intraperitoneal administration of streptozotocin (45 mg/kg) 
effectively induced diabetes in normal rats as reflected by glycosuria, hyperglycaemia, 
polyphagia, polydipsia and body weight loss when compared with normal rats [25]
. 
In our 
present study we have observed that Euphorbia neriifolia stem bark extract of can reverse these 
effects. The possible mechanism by which MEEN brings about its antihyperglycemic action  
may be by potentiation of pancreatic secretion of insulin from β -cell of islets or due to enhanced 
transport of blood glucose to peripheral tissue. This was clearly evidenced by the increased level 
of insulin in diabetic rats treated with MEEN. In this context a number of other plants have also 
been reported to have antihyperglycemic and insulin-release stimulatory effect
 
[26, 27]. 
We have observed a decrease in total haemoglobin during diabetes and this may be due to the 
formation of glycosylated haemoglobin. Increase in the level of haemoglobin in animals given 
MEEN may be due to decreased level of blood glucose 
MEEN administration to streptozotocin dosed animals reversed the weight loss. The ability of 
MEEN to recover body weight loss seems to be due to its antihyperglycemic effect. Excess of 
fatty acids in serum produced by the streptozotocin-induced diabetes promotes conversion of 
excess fatty acids into phospholipids and cholesterol in liver. These two substances along with 
excess triglycerides formed at the same time in liver may be discharged into blood in the form of 
lipoproteins
 
[28]. The abnormal high concentration of serum lipids in the diabetic subject is due, 
mainly to increase in the mobilisation of free fatty acids from the peripheral fat depots, since 
insulin inhibits the hormone sensitive lipase. Hypercholesterolemia and hypertriglyceridemia 
have been reported to occur in streptozotocin diabetic rats [29, 30] and significant increase 
observed in our experiment was in accordance to these studies. The marked hyperlipidaemia that 
characterise the diabetic state may therefore be regarded as a consequence of the uninhibited 
actions of lipolytic hormones on the fat depots
 
[31]. 
The antihyperlipidaemic effect of MEEN may be due to the down regulation of NADPH and 
NADH, a cofactor in the fat metabolism. Higher activity of glucose-6-phosphatase provides H+ 
which binds with NADP+ in the form of NADPH and is helpful in the synthesis of fats from 
 carbohydrates. When glycolysis slows down because of cellular activity, the pentose phosphate 
pathway still remain active in liver to breakdown glucose that continuously provides NADPH 
which converts acetyl radicals into long fatty acid chains. MEEN may be capable of oxidising 
NADPH. Enhanced hexokinase activity in MEEN treated rats suggests greater uptake of glucose 
from blood by the liver cells. 
Activities of enzymes suggest that enhanced lipid metabolism during diabetes is shifted towards 
carbohydrate metabolism and it enhances the utilisation of glucose at the peripheral sites. One of 
the possible actions of MEEN may be due to its inhibition of endogenous synthesis of lipids. 
Metabolic aberrations in streptozotocin diabetic rats suggest a high turnover of triglycerides and 
phospholipids. MEEN may antagonise the metabolic aberration and thereby restore the normal 
metabolism by tilting the balance from high lipids to high carbohydrate turnover. Alteration of 
fatty acid composition by increased lipid levels contribute to lowering the resistance of tissues 
and higher rate of oxidative stress. Decreased activity of glucose-6-phosphatase through pentose 
phosphate shunt results in high reduced glutathione to oxidised glutathione ratio (GSH/GSSG) 
[30]
,
 which is coupled with conversion of NADPH to NADP. MEEN may produce high NADP+ 
which results in down regulation of lipogenesis and lower risk of the tissues for oxidative stress 
and high resistance for diabetes. 
It can be concluded from the data that MEEN significantly reduces the levels of serum and tissue 
lipids, which are actively raised in streptozotocin diabetes rats. MEEN has beneficial effect on 
plasma insulin and hexokinase activity. Moreover its antihyperlipidaemic effect and antidiabetic 
could represent a protective mechanism against the development of diabesity. 
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